Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?

Bibliography

• Tavassoli F, Deville P. World Health Organization: tumours of the breast and female genital organs (Who/IARC Classifications of Tumours). IARC, Lyon;2003
   Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular porttraits of human breast tumours. Nature 2000;406(6797):747-52
   PubMed Web of Science ®Google Scholar
• Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004;40:2667-75
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008;123:236-40
   PubMed Web of Science ®Google Scholar
• Cleator S, Heller W, Coombes R. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;3:235-44
   Google Scholar
• Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65
   PubMed Web of Science ®Google Scholar
• Nielsen T, Hsu F, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74
   PubMed Web of Science ®Google Scholar
• Böcker W, Bier B, Freytag G, et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I: normal breast and benign proliferative lesions. Virchows Arch A Pathol Anat Histopathol 1992;421:315-22
   PubMedGoogle Scholar
• Gottlieb C, Raju U, Greenwald K. Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: an immunohistochemical study. Mod Pathol 1990;3:135-40
   PubMed Web of Science ®Google Scholar
• Lazard D, Sastre X, Frid M, et al. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc Natl Acad Sci USA 1993;90:999-1003
   PubMed Web of Science ®Google Scholar
• Nakano S, Iyama K, Ogawa M, et al. Differential tissular expression and localization of type IV collagen alpha1(IV), alpha2(IV), alpha5(IV), and alpha6(IV) chains and their mRNA in normal breast and in benign and malignant breast tumors. Lab Invest 1999;79:281-92
   PubMed Web of Science ®Google Scholar
• Nayar R, Breland C, Bedrossian U, et al. Immunoreactivity of ductal cells with putative myoepithelial markers: a potential pitfall in breast carcinoma. Ann Diagn Pathol 1999;3:165-73
   PubMedGoogle Scholar
• Rudland P. Histochemical organization and cellular composition of ductal buds in developing human breast: evidence of cytochemical intermediates between epithelial and myoepithelial cells. J Histochem Cytochem 1991;39:1471-84
   PubMed Web of Science ®Google Scholar
• Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-33
   PubMed Web of Science ®Google Scholar
• Troester M, Herschkowitz J, Oh D, et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006;6:276
   PubMed Web of Science ®Google Scholar
• Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005;11:4003-11
   PubMed Web of Science ®Google Scholar
• Foulkes W, Stefansson I, Chappuis P, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-5
   PubMed Web of Science ®Google Scholar
• James C, Quinn J, Mullan P, et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007;12:142-50
   PubMed Web of Science ®Google Scholar
• Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: True basal phenotype confined to brca1 tumors. Mod Pathol 2005;18:1321-8
   PubMed Web of Science ®Google Scholar
• Lakhani S, Reis-Filho J, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34
   PubMed Web of Science ®Google Scholar
• Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113(10):2638-45
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81
   PubMed Web of Science ®Google Scholar
• Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-91
   PubMed Web of Science ®Google Scholar
• Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-68
   PubMed Web of Science ®Google Scholar
• Yi S, Uhm J, Cho E, et al. Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. J Clin Oncol 2008;26(suppl):abstract 1008
   PubMedGoogle Scholar
• Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative (TN) breast cancer. Ann Oncol 2008;19(11):1847-52
   PubMed Web of Science ®Google Scholar
• Chia JW, Ang P, See H, et al. Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):1086
   Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Yoffe M, Osborne C, et al. Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. SABCS, San Antonio, Texas, 10 - 14 December, 2008: abstract 2120
   Google Scholar
• O'shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. Program and abstracts of the 2009 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2009; Orlando, Florida: abstract 3
   Google Scholar
• Li HC, Russell CA. Gemcitabine and platinum-based chemotherapy in metastatic breast cancer. Oncology 2004;18:17-22
   PubMedGoogle Scholar
• Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Program and abstracts of the 2009 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2009; Orlando, Florida: abstract CRA 501
   Google Scholar
• Clinical trial details for AZD2281 and carboplatin in treating patients with BRCA1/BRCA2-associated or hereditary metastatic or unresectable breast and/or ovarian cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00647062?term=azd2281&rank=10
   Google Scholar
• Zelek l, Lyovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006;94:1610-14
   PubMed Web of Science ®Google Scholar
• Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009;45(7):1153-61
   PubMed Web of Science ®Google Scholar
• Delaloge S, Tedesco KL, Blum J, et al. Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). Program and abstracts of the 2009 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2009; Orlando, Florida: abstract 1010
   Google Scholar
• Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep 2009;21(2):413-7
   PubMed Web of Science ®Google Scholar
• Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008;26(suppl):abstract 1009
   Google Scholar
• O'Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. SABCS, San Antonio, Texas, 13 - 16 December, 2007:abstract 308
   Google Scholar
• Hobday TJ, Stella PJ, Fitch TR, et al. N0436: a phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. J Clin Oncol 2008;26(suppl):abstract 1081
   Google Scholar
• Thome S, Hobday T, Hillman D, et al. Translational correlates, including outcome for patients with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):1071
   Google Scholar
• Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009;20(5):862-7
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53/glomeruloidmicrovascular-proliferation) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-5
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Kabbinavar FF, Allen HJ, et al. A phase 2 trial of docetaxel with bevacizumab as first-line therapy for HER2/NEU-negative metastatic breast carcinoma. Program and abstracts of the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Texas: abstract 4062
   Google Scholar
• Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Program and abstracts of the 44th American Society of Clinical Oncology Annual Meeting; May 30 - June 3, 2008; Chicago, Illinois: abstract LBA1011
   Google Scholar
• Modi S, Seidman AD, Dickler M, et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005;90(2):157-63
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Morandi P, Krishnamurthy S, et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 2008;19(10):1713-9
   PubMed Web of Science ®Google Scholar
• Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004;10(Pt 1):178-83
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26(11):1810-6
   PubMed Web of Science ®Google Scholar
• Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19(8):1379-86
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/‘triple-negative’ breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-26
   PubMed Web of Science ®Google Scholar
• Huang F, Reeves K, Han K, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38
   PubMed Web of Science ®Google Scholar
• Finn RS, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. Program and abstracts of the 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, Texas: abstract 3118
   Google Scholar
• Ixempra TM, package insert. Bristol-Myers Squibb, Princeton, NJ, USA; 2007
   Google Scholar
• Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7
   PubMed Web of Science ®Google Scholar
• Rugo HS, Thomas ES, Lee RK, et al. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes [abstract 6069]. Breast Cancer Res Treat 2007;106(suppl 1):S270
   Google Scholar
• Hortobagyi GN, Perez E, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trial. 2008 Breast Cancer Symposium, Washington, DC, 5 - 7 September, 2008: abstract 186
   Google Scholar
• De Giorgi U, Rosti G, Frassinetti L, et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol 2007;18(1):202-3. [Epub 13 September 2006]
   PubMed Web of Science ®Google Scholar